APPOINTMENT We delighted to announce that Paolo Paoletti, MD, has joined our Board of Directors as an independent Non Executive Director (#NED). Paolo has extensive experience in the life science sector, with a strong focus on oncology and precision medicine. He was previously CEO at GammaDelta Therapeutics and the first President of GSK Oncology. Prior pharma roles included at Eli Lilly and Company and his academic career has included Professor of Pulmonary Medicine at the University of Pisa. He is currently a member of the Board of Genmab, member of the Investment Committees of Apollo Therapeutics and 3B Future Health Fund I & II, and Scientific Advisor to dawn-bio. Welcoming him to the board, Chris Martin, our Chairman and NED said, “Paolo brings extensive leadership experience in R&D and commercialisation in the pharma and biotech industry which will be invaluable as we advance our N-Myristoyltransferases inhibitor (#NMTi) ADCs towards clinical development.” Read the full release here - https://lnkd.in/dMmrWiGK #appointment #drugdevelopment #ADC
Myricx Bio
Biotechnology Research
Developing a new class of ADCs based on NMT inhibition to treat cancer
About us
We are a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.
- Website
-
https://myricxbio.com/
External link for Myricx Bio
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- London
- Type
- Privately Held
Locations
-
Primary
Kings Cross
London, GB
Employees at Myricx Bio
Updates
-
World Cancer Research Day celebrates the collaborative efforts of researchers across the globe striving to develop innovative therapies to make a difference to people living with cancer. Despite truly groundbreaking advances in precision oncology approaches, cancer remains the second leading cause of death worldwide. We can help change that. The antibody-drug conjugate (#ADC) area is one of the most promising modalities in cancer therapy - but new payloads are urgently needed. Myricx Bio has developed a proprietary N-Myristoyltransferase inhibitor (#NMTi) ADC payload platform and is funded to advance our pipeline of first-in-class NMTi-ADCs through clinical proof of concept testing targeting clinically validated tumour-associated antigens. Visit our website to find out more www.myricxbio.com #WCRD24 #WorldCancerResearchDay #oncology #drugdiscovery #innovation
-
Great to have now moved into our own integrated lab and office facilities in the #London Innovation Centre in Canary Wharf, an ideal location to push ahead with our R&D to advance our novel NMTi antibody drug conjugate drugs towards the clinic. Exciting times ahead. Thanks for a warm welcome Kadans Science Partner and other members of the life sciences ecosystem. #innovation #UKBiotech #drugdevelopment #adc
We welcome Myricx Bio to the London Innovation Centre, following a recent £90m Series A financing! 🏙️ 🔬 Myricx Bio, an innovative UK biotech company focused on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs) for the treatment of cancer, will move its headquarters to the London Innovation Centre, taking a mix of laboratory and office space. 🏢 Myricx Bio COO, Julie Mead commented: “We are excited to take this next step and join Kadans’ London Innovation Centre as we grow our in-house R&D capabilities and management team, following the recent close of our £90m Series A financing. When looking to expand our footprint, it was important to us that we located a supportive, well-connected and dynamic environment in London, where we were founded, especially as we prepare to become a clinical stage company." 🥼🧪The London Innovation Centre provides flexible, fully serviced CL2 wet-lab laboratory and innovative workspaces for early-stage life science, biology and pharma organisations. Myricx joins a host of life sciences and healthcare organisations already based at the London Innovation Centre as well as wider Canary Wharf tenants. 📰 Read more: https://lnkd.in/ewa_rdtV Katie Nelson Mark Hanna FRICS James Sheppard Oli Appleyard Leon Mehtab MRICS Claudia Tripp Ricky Williams Canary Wharf Group #LifeScience #CancerTreatment #Research #LabandOfficespace #CanaryWharf #LondonInnovationCentre
-
AWARD NEWS: We are thrilled to have been named as a finalist in the Series A Financing of the Year category of the 2024 European Lifestars Awards - Celebrating Life Science Leaders. We announced our £90m ($114m) series A financing in July, one of the largest biotech series A in European biotech and the largest in the UK this year. The round was co-led by new investors Novo Holdings and Abingworth. Additional new investors British Patient Capital, Cancer Research Horizons and @Lilly also participated alongside founding investors Brandon Capital and Sofinnova Partners. The series A funds are enabling us to build out our proprietary N-Myristoyltransferase inhibitor (#NMTi) antibody-drug conjugate (#ADC) payload platform and advance our pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigens. The ADC area is one of the most promising modalities with new payloads urgently needed and we are pleased to be making excellent progress with our programmes. Winners will be announced on November 18 at Awards Dinner in London. We are looking forward to celebrating our life science industry’s achievements there! View the table of finalists across all categories and regions here https://lnkd.in/dNeDbkCx. Congratulations and good luck to all. #awards #venturecapital #drugdevelopment #precisiononcology #ukbiotech #lifesciences
-
WELCOME: Following our £90m ($114m) Series A financing, we are delighted to welcome Lucille Conroy, Principal at our new investor Abingworth, to our board. The ADC area is one of the most promising modalities and new payloads are urgently needed. The series A funds enable us to build out our proprietary N-Myristoyltransferase inhibitor (#NMTi) antibody-drug conjugate (#ADC) payload platform and advance our pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigens. As an investment manager within a leading and highly experienced venture group, we look forward to Lucille’s contribution to our strategy to deliver life changing treatments to patients. She joins board members - Chris Martin (independent chair), Robin Carr (CEO), Maina Bhaman, Partner at Sofinnova Partners, Jonathan Tobin, Partner at Brandon Capital and Michael Bauer, Ph.D., Partner in the Venture Investments group at Novo Holdings. #appointment #drugdevelopment #UKbiotech
-
WELCOME: Following our £90m ($114m) Series A financing, we are delighted to welcome Michael Bauer, Ph.D., Partner in the Venture Investments group at our new investor Novo Holdings, to our board. The series A funds enable us to build out our proprietary N-Myristoyltransferase inhibitor (#NMTi) antibody-drug conjugate (#ADC) payload platform and advance our pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigens. The ADC area is one of the most promising modalities and new payloads are urgently needed. As a seasoned investment manager within the venture investments group of a major pharma, we look forward to Michael’s contribution to our strategy to deliver life changing treatments to patients. He joins board members - Chris Martin (independent chair), Robin Carr (CEO), Maina Bhaman, Partner at Sofinnova Partners, Jonathan Tobin, Partner at Brandon Capital and Lucille Conroy, Principal at Abingworth. #appointment #drugdevelopment #UKbiotech
-
READ - the story of our history. Brilliant insights and innovation by our founding team Ed Tate Andy Bell and Roberto Solari. Excellent support and teamwork from our founding investors Brandon Capital and Sofinnova Partners. Thank you CRUK for supporting our journey. Exciting times ahead. #teamwork #innovation #resilience
The journey to drug development and success is never easy, and spin-out company Myricx Bio knows this all too well. Recently securing one of the largest Series A investments, Myricx Bio has developed first-in-class N-myristoyltransferase (NMT) inhibitors as #ADC payloads, showing promising preclinical results with complete and durable tumour regression. Now on the path to the clinic, we spoke with co-founder Ed Tate. He shared their remarkable journey, from targeting anti-malarial treatments and potentially curing the common cold to developing a promising oncology drug. Hear more from Ed 👉 https://bit.ly/4eOyjEW Imperial College London | The Francis Crick Institute
-
BOARD CHANGES: Following our £90m ($114m) series A financing, we are pleased to announce the following board changes. Dr Rachael Brake has stepped down as an independent Non-Executive Director. She joined us in 2022 and has made a tremendous contribution to the company through our transformative evolution both within and outside of board meetings. Thank you. Co-founder Professor Ed Tate has stepped down as Director but remains a Board Observer and closely involved with the company as a N-Myristoyltransferase (#NMT) key opinion leader and Scientific Advisor to the company. Michael Karl Bauer from Novo Holdings and Lucille Conroy from Abingworth have joined the Myricx’ Board as Investor Directors. Other board directors are Chris Martin, Independent Chair, Robin Carr, CEO, and Maina Bhaman from Sofinnova Partners and Jonathan Tobin from Brandon Capital as Investor Directors. We look forward to working together to execute on our strategy to build out our proprietary N-Myristoyltransferase inhibitor (#NMTi) antibody-drug conjugate (#ADC) payload platform and advance our pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigens. Read the full release HERE https://lnkd.in/evhq7mVD #appointment #drugdevelopment #UKbiotech #ADC
-
It was a pleasure meeting BiotechTV new European correspondent Amy Brown and explaining our excitement around the prospects for our #NMTi-ADCs. Great to be financed to take two programs into the clinic and further develop our NMTi payload platform.
𝐅𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐢𝐧𝐠 𝐍𝐞𝐰𝐬: London based Myricx Bio announced a £90M (~$114M) series A financing today, one of the largest in recent years in the UK region. A developer of ADCs today, CEO Robin Carr describes how the company’s N-myristoyltransferase (NMT) payload approach sets them apart. Full video: https://lnkd.in/gt-GapCu BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
FUNDING NEWS: We are thrilled to announce our £90m ($114m) series A financing, one of the largest biotech series A in European biotech and the largest in the UK this year. The round was co-led by new investors Novo Holdings and Abingworth. Additional new investors British Patient Capital, Cancer Research Horizons and Eli Lilly and Company also participated alongside founding investors Brandon Capital and Sofinnova Partners. The series A funds enable us to build out our proprietary N-Myristoyltransferase inhibitor (#NMTi) antibody-drug conjugate (#ADC) payload platform and advance our pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigens. The ADC area is one of the most promising modalities and new payloads are urgently needed. Having been a virtual company since spinning out from Imperial College London and The Francis Crick Institute, we will now move to establish laboratory operations in London’s biotech hub and will be expanding our management and R&D teams. Welcome to our new investors and thank you to everyone that has contributed to the progress of the company so far, not least our founding scientists Ed Tate, Roberto Solari and Andy Bell. Exciting times ahead. Read the full release HERE https://lnkd.in/eSu9mP3c #venturecapital #financing #drugdevelopment #UKbiotech